Segment Information

3 Months Ended

Apr. 02, 2016

Segment Reporting [Abstract]

Segment reporting disclosure [Text Block]

SEGMENT INFORMATION

Our reporting segments are as follows:

• CHCis focused primarily on the global sale of OTC store brand products including cough, cold, allergy, and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, VMS, animal health, and diagnostic products.

• BCHdevelops, manufactures, markets and distributes many well-known European OTC brands in the natural health and VMS, cough, cold and allergy, smoking cessation, personal care and derma-therapeutics, lifestyle, and anti-parasite categories.

• Rxdevelops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and U.K. markets.

• Specialty Sciences is comprised primarily of royalties received from assets focused on the management of multiple sclerosis (Tysabri^®).

We also have an Other reporting segment that consists of our API business, which does not meet the quantitative threshold required to be a separately reportable segment. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.

The below tables show select financial measures by reporting segment (in millions):

	Three Months Ended							April 2, 2016
	April 2, 2016
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
CHC	$	700.3	$	102.5		$	19.8	$	4,026.5
BCH	317.6		(482.7		)	35.4		6,238.2
Rx	256.7		87.4			29.5		3,384.5
Specialty Sciences	88.0		12.9			72.8		5,859.6
Other	20.6		5.4			0.5		217.4
Unallocated	—		(29.3		)	—		—
Total	$	1,383.2	$	(303.8	)	$	158.0	$	19,726.2

	Three Months Ended							December 31, 2015
	March 28, 2015
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
CHC	$	684.9	$	104.3		$	16.2	$	4,007.8
BCH	—		—			—		6,324.0
Rx	251.6		100.0			18.3		3,015.5
Specialty Sciences	81.9		5.5			72.8		5,833.5
Other	30.7		10.5			0.5		213.1
Unallocated	—		(21.1		)	—		—
Total	$	1,049.1	$	199.2		$	107.8	$	19,393.9